CHAPEL HILL, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the Guggenheim 2nd Annual Healthcare Innovation Conference, which is taking place from November 10-12, 2025, in Boston, MA. Details of presentation: Format: Fireside chat Participants: Chris Giordano, Presiden ...

Germany's BioNTech on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol Myers Squibb in a cancer immunotherapy alliance that seeks to challenge Merck's best-selling Keytruda. ...

Core Insights - Manifold Bio has announced a strategic research collaboration and license agreement with Roche to enhance drug discovery for neurological and neurodegenerative diseases [1] Company Overview - Manifold Bio is a platform therapeutics company that specializes in AI-guided drug discovery and direct-to-vivo measurement [1] - The company utilizes a proprietary tissue-targeting shuttle portfolio and an AI-driven in vivo discovery engine called mDesign [1] Partnership Details - The collaboration with Roche aims to develop multiple next-generation blood-brain barrier (BBB) shuttles [1] - This partnership is focused on creating innovative treatments for neurological and neurodegenerative disorders [1]

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S. ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes. ...

Group 1 - Pfizer is currently facing significant challenges, with its stock down approximately 60% from its 2022 peak, resulting in a high dividend yield of around 7% [1] - The company is dealing with upcoming patent expirations for key drugs, including Ibrance, Eliquis, and Vyndaqel, which are set to lose patent protection in 2027 and 2028 [3] - The pharmaceutical industry is experiencing increased pressure regarding drug pricing, particularly in the U.S., with potential government intervention and regulatory changes [4] Group 2 - Pfizer has a history of adapting to industry challenges and is currently making strategic moves to ensure long-term success, including a notable acquisition [6] - The company has agreed to acquire Metsera for $47.50 per share in cash, totaling around $4.9 billion, with additional potential earn-outs that could increase the overall cost [8] - Management is actively working with the U.S. government to better navigate changing regulations and position the company for future growth [7]

Core Insights - The training course titled "Global Regulatory Requirements for Drug Safety & Pharmacovigilance" is aimed at pharmaceutical and biologic companies in the US and EU, focusing on product safety regulatory requirements [1][2]. Group 1: Training Course Overview - The course is designed to help companies understand the latest compliance expectations in pharmacovigilance to maintain product marketability [2]. - It emphasizes the importance of having adequate systems and processes for safety reporting to avoid significant consequences, including product recalls [2]. Group 2: Learning Objectives - Participants will learn about the regulatory requirements for drug safety, including the US, EU, and UK frameworks, and specific details regarding EU GVP modules [6]. - The course will cover the contents of the Pharmacovigilance System Master File (PSMF) and the requirements for quality oversight of drug safety [6]. - Key topics include signal management regulations, UK QPPV responsibilities, and penalties for non-compliance [6][8]. Group 3: Target Audience - The training is relevant for nearly all individuals involved in drug development and marketing, including executives with legal responsibilities for drug safety [5][6]. Group 4: Instructor Profile - The course will be led by Steve Jolley, a subject matter expert with 37 years of experience in drug safety and pharmacovigilance, who has worked with over 300 clients globally [10][12].

Key Points Pfizer has long been a solid dividend payer, having raised its dividend annually for 16 years. Its yield is high because the stock price has fallen in recent years. That has given it an appealing valuation. 10 stocks we like better than Pfizer › I can think of more than a few reasons why someone might want to invest in Pfizer (NYSE: PFE), the pharmaceutical giant. The best one, for me at the moment, is its huge dividend yield -- 7% as of Friday. Consider that the best high-yield bank s ...

Core Points - Kyowa Kirin International has appointed Julie Dehaene-Puype as President for the Region, effective November 1, 2025 [1] - Julie Dehaene-Puype succeeds Jeremy Morgan, who has been serving as President for the International Region since 2023 [1] - Jeremy Morgan will transition to an advisory role within the business following his tenure [1]

Group 1 - European companies are demonstrating remarkable adaptability to U.S. tariff barriers, with a Goldman Sachs portfolio of affected European stocks outperforming the market by approximately 6% in October, double the gain of the Stoxx Europe 600 index [1] - Major European firms like Hermès, Unilever, and Galderma Group AG attribute their better-than-expected performance and raised guidance to strong demand in the U.S. market [1][2] - The frequency of the term "tariff" in earnings calls is decreasing, indicating that corporate management's concerns about tariffs are diminishing [1] Group 2 - The U.S. market has become a key growth driver for many European companies, with Hermès reporting a 14.1% sales increase in its regional markets, and Unilever crediting strong North American demand for its sales performance [2] - Galderma raised its full-year guidance based on strong U.S. sales, while other companies like Haleon Plc and Stellantis also reported unexpected sales growth in North America [2] Group 3 - Companies are adapting to tariff challenges by cutting costs, adjusting production layouts, and increasing investments in the U.S. [3] - Pharmaceutical companies like Novartis and GSK are negotiating with the U.S. government for price reductions in exchange for future tariff exemptions, with AstraZeneca reaching an agreement in October [3] Group 4 - Despite overall optimism, the impact of tariffs is not uniform, with some companies like Rémy Cointreau and Pernod Ricard warning of weaker-than-expected recovery in specific markets [4] - Market sentiment is shifting towards the view that tariffs are manageable, although some analysts caution against premature conclusions regarding their impact [4][5]